FDA Alert: FDA Approves Xarelto to Prevent Stroke in People with Common Type of Abnormal Heart Rhythm

November 4, 2011

Share:

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation).

Read the FDA News Release.